The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)-Reference-Cited by-同舟云学术

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

Published:2008-09-25 Issue:1 Volume:23 Page:153-161
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Buske C,Hoster E,Dreyling M,Eimermacher H,Wandt H,Metzner B,Fuchs R,Bittenbring J,Woermann B,Hohloch K,Hess G,Ludwig W-D,Schimke J,Schmitz S,Kneba M,Reiser M,Graeven U,Klapper W,Unterhalt M,Hiddemann W

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2008261.pdf

Reference31 articles.

1. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G et al. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292–293.

2. Treon SP, Dimopoulos M, Kyle RA . Defining Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 107–109.

3. Treon SP, Morel P, Leblond V, Fermand JP . Report of the Third International Workshop on Waldenstrom's macroglobulinemia. Clin Lymphoma 2005; 5: 215–216.

4. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP . Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23: 1564–1577.

5. Papamichael D, Norton AJ, Foran JM, Mulatero C, Mathews J, Amess JA et al. Immunocytoma: a retrospective analysis from St Bartholomew's Hospital-1972–1996. J Clin Oncol 1999; 17: 2847–2853.

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy;American Journal of Ophthalmology Case Reports;2024-12

2. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-01

3. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy;Hematology/Oncology Clinics of North America;2023-08

4. Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster;Cancers;2022-11-10

5. First-Line Treatment of Waldenström’s Macroglobulinaemia: Considerations Based on the Dutch National Guideline;Hemato;2022-10-26